State regulations associated with late-stage cancer diagnoses
the ONA take:
According to a new study conducted by researchers at Georgia State University's School of Public Health in Atlanta and the University of North Carolina at Chapel Hill, state regulations of health insurance and practitioners are significantly associated with time receive breast or colorectal cancer diagnoses.
For the study, researchers evaluated states' regulatory policies and cancer cases reported between 2004 and 2009 in 40 states using the United States Cancer Statistics (USCS) database.
Results showed that 54% to 60% of newly diagnoses cases of colorectal cancer are diagnosed as late-stage cancer, and 24% to 36% of newly diagnosed breast cancers are diagnosed as late-stage.
Of note, the study was conducted between 2010 when the Affordable Care Act was enacted, making cancer screenings more widely available to Americans.
The study was published in the journal Health Economics Review.
State regulations of health insurance and practitioners are significantly associated with time receive breast or colorectal cancer diagnoses.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|